Home » Authors » Cormac Sheridan

Articles by Cormac Sheridan

Newron Plans Funding Round As CNS Drug Nears Phase III

Dec. 3, 2003

By Cormac Sheridan

Abbott Pulls Out Of Diabetes Collaboration With Karo Bio

Nov. 19, 2003

By Cormac Sheridan

Abbott Pulls Out Of Diabetes Collaboration With Karo Bio

Nov. 19, 2003

By Cormac Sheridan

T-cellic Raises DKK40M For Its T-Cell Guided Therapy'

Nov. 12, 2003

By Cormac Sheridan

T-cellic Raises DKK40M For Its T-Cell Guided Therapy'

Nov. 12, 2003

By Cormac Sheridan

Swedish Research Coalition Seeking More R&D Support

Nov. 5, 2003

By Cormac Sheridan

Swedish Research Coalition Seeking More R&D Support

Nov. 5, 2003

By Cormac Sheridan

XCellentis Reports Positive Phase II LyphoDerm Results

Oct. 29, 2003

By Cormac Sheridan

Focused On Drug Development, BioInvent In-Licenses Program

Oct. 29, 2003

By Cormac Sheridan

XCellentis Reports Positive Phase II LyphoDerm Results

Oct. 29, 2003

By Cormac Sheridan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...